FOLLOWUS
Protective effects of traditional Tibetan medicine Zuo-Mu-A Decoction (佐木阿汤) on the blood parameters and myocardium of high altitude polycythemia model rats
- Chinese Journal of Integrative Medicine Vol. 23, Issue 12, Pages: 908-915(2017)
- Affiliations：
1. School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine,Beijing,China
2. Tibetan Traditional Medical College,Lhasa,China
3. Department of Tuina, Beijing Massage Hospital,Beijing,China
4. Information Center, Beijing University of Chinese Medicine,Beijing,China
5. Tibet Academy of Tibetan Medicine,Lhasa,China
6. Center of Scientific Experiment, Beijing University of Chinese Medicine,Beijing,China
- Author bio：
- Funds：Supported by the National Natural Science Foundation of China (No. 81260567)
DOI：10.1007/s11655-016-2500-7
CLC：Published：2017，
Published Online：4 May 2016，
Scan for full text
Lu, Mq., Tsring, N., Yu, Ty. et al. Protective effects of traditional Tibetan medicine Zuo-Mu-A Decoction (佐木阿汤) on the blood parameters and myocardium of high altitude polycythemia model rats., Chin. J. Integr. Med. 23, 908–915 (2017). https://doi.org/10.1007/s11655-016-2500-7
Meng-qian Lu, Nyima Tsring, Tian-yuan Yu, et al. Protective effects of traditional Tibetan medicine Zuo-Mu-A Decoction (佐木阿汤) on the blood parameters and myocardium of high altitude polycythemia model rats. [J]. Chinese Journal of Integrative Medicine 23(12):908-915(2017)
Lu, Mq., Tsring, N., Yu, Ty. et al. Protective effects of traditional Tibetan medicine Zuo-Mu-A Decoction (佐木阿汤) on the blood parameters and myocardium of high altitude polycythemia model rats., Chin. J. Integr. Med. 23, 908–915 (2017). https://doi.org/10.1007/s11655-016-2500-7 DOI：
Meng-qian Lu, Nyima Tsring, Tian-yuan Yu, et al. Protective effects of traditional Tibetan medicine Zuo-Mu-A Decoction (佐木阿汤) on the blood parameters and myocardium of high altitude polycythemia model rats. [J]. Chinese Journal of Integrative Medicine 23(12):908-915(2017) DOI： 10.1007/s11655-016-2500-7.
摘要
To explore the protective effects of Tibetan medicine Zuo-Mu-A Decoction (佐木阿汤
ZMAD) on the blood parameters and myocardium of high altitude polycythemia (HAPC) model rats. Forty male Wistar rats were randomly divided into 4 groups by a random number table
including the normal
model
Rhodiola rosea L. (RRL) and ZMAD groups (10 in each group). Every group was raised in Lhasa to create a HAPC model except the normal group. After modeling
rats in the RRL and the ZMAD groups were administered intragastrically with RRL (20 mL/kg) and ZMAD (7.5 mL/kg) once a day for 2 months
respectively; for the normal and the model groups
5 mL of distilled water was administered intragastrically instead of decoction. Then routine blood and hematologic rheology parameters were taken
levels of erythropoietin and 8-hydroxy-2'-deoxyguanosine (8-OHdG) were tested
and ultrastructural change in the left ventricular myocardium was observed using transmission electron microscopy. Compared with the model group
ZMAD significantly reduced the red blood cell count
hemoglobin levels
whole blood viscosity at low/middle shear rates
plasma viscosity
erythrocyte electrophoretic time
erythropoietin and 8-OHdG levels
and also increased the erythrocyte deformation index (P<0.05). There was no difference in all results between the RRL and the ZMAD groups. The cardiac muscle fibers were well-protected
mitochondrial matrix swelled mildly and ultrastructure changes were less prominent in the ZMAD group compared with the model group. ZMAD has significant protective effects on the blood parameters against HAPC
and also has the beneficial effect in protecting against myocardial injury.
Abstract
To explore the protective effects of Tibetan medicine Zuo-Mu-A Decoction (佐木阿汤
ZMAD) on the blood parameters and myocardium of high altitude polycythemia (HAPC) model rats. Forty male Wistar rats were randomly divided into 4 groups by a random number table
including the normal
model
Rhodiola rosea L. (RRL) and ZMAD groups (10 in each group). Every group was raised in Lhasa to create a HAPC model except the normal group. After modeling
rats in the RRL and the ZMAD groups were administered intragastrically with RRL (20 mL/kg) and ZMAD (7.5 mL/kg) once a day for 2 months
respectively; for the normal and the model groups
5 mL of distilled water was administered intragastrically instead of decoction. Then routine blood and hematologic rheology parameters were taken
levels of erythropoietin and 8-hydroxy-2'-deoxyguanosine (8-OHdG) were tested
and ultrastructural change in the left ventricular myocardium was observed using transmission electron microscopy. Compared with the model group
ZMAD significantly reduced the red blood cell count
hemoglobin levels
whole blood viscosity at low/middle shear rates
plasma viscosity
erythrocyte electrophoretic time
erythropoietin and 8-OHdG levels
and also increased the erythrocyte deformation index (P<0.05). There was no difference in all results between the RRL and the ZMAD groups. The cardiac muscle fibers were well-protected
mitochondrial matrix swelled mildly and ultrastructure changes were less prominent in the ZMAD group compared with the model group. ZMAD has significant protective effects on the blood parameters against HAPC
and also has the beneficial effect in protecting against myocardial injury.
关键词
erythropoietinhematologymyocardiumhigh altitude polycythemiaTraditional Medicine
Keywords
erythropoietinhematologymyocardiumhigh altitude polycythemiaTraditional Medicine
references
Moore LG. Human genetic adaptation to high altitude. High Alt Med Biol 2001;2:257–279.
Beall CM, Brittenham GM, Strohl KP, Blangero J, Williams BS, Goldstein MC. Hemoglobin concentration of highaltitude Tibetans and Bolivian Aymara. Am J Phys Anthropol 1998;106:385–400.
Monge CC, Arrequi A, Leon VF. Pathophysiology and epidemiology of chronic mountain sickness. Int J Sports Med 1992;13:79–81.
Beall CM, Goldstein MC. Hemoglobin concentration of pastoral nomads permanently residing at 4850–5450 m in Tibet. Am J Phys Anthropol 1987;73:433–438.
Wu TY, Wang X, Wei C, Cheng H, Wang X, Li Y, et al. Hemoglobin levels in Qinghai-Tibet: different effects of gender for Tibetans vs Han. J Appl Physiol 2005;98:598–604.
Velarde FL, Maggiorini M, Reeves JT, Aldashev A, Asmus I, Bernardi L, et al. Consensus statement on chronic and subacute high altitude diseases. High Alt Med Biol 2005;6:147–157.
Reeves JT, Leon VF. Chronic mountain sickness: recent studies of the relationship between hemoglobin concentration and oxygen transport. High Alt Med Biol 2004;5:147–155.
West JB. English translation of "Nomenclature, classification, and diagnostic criteria of high altitude disease in China". High Alt Med Biol 2010;11:169–172.
Rivera-Ch M, Leon-Velarde F, Huicho L. Treatment of chronic mountain sickness: critical reappraisal of an old problem. Respir Physiol Neurobiol 2007;158:251–265.
Wu TY, ed. Guidelines for the diagnosis, prevention and treatment of high altitude disease. Lanzhou: Lanzhou University Press; 2014:163.
Penaloza D, Arias-Stella J. The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. Circulation 2007;115:1132–1146.
Cruz JC, Diaz C, Marticorena E, Hilario V. Phlebotomy improves pulmonary gas exchange in chronic mountain polycythemia. Respiration 1979;38:305–313.
Winslow RM, Monge CC, Brown EG, Klein HG, Sarnquist F, Winslow NJ, et al. Effects of hemodilution on O2 transport in high-altitude polycythemia. J Appl Physiol 1985;59:1495–1502.
Kryger M, McCullough RE, Collins D, Scoggin CH, Weil JV, Grover RF. Treatment of excessive polycythemia of high altitude with respiratory stimulant drugs. Am Ver Respir Dis 1978;117:455–464.
Richalet JP, Rivera CM, Maignan M, Privat C, Pham I, Macarlupu JL, et al. Acetazolamide for Monge's disease: Efficiency and tolerance of 6-month treatment. Am J Respir Crit Care Med 2008;177:1370–1376.
Richalet JP, Rivera M, Bouchet P, Chirinos E, Onnen I, Petitjean O, et al. Acetazolamide: a treatment for chronic mountain sickness. Am J Respir Crit Care Med 2005;172:1427–1433.
Plata R, Cornejo A, Arratia C, Anabaya A, Perna A, Dimitrov BD, et al. Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. Lancet 2002;359:663–666.
Berg JT. Ginkgo biloba extract prevents high altitude pulmonary edema in rats. High Alt Med Biol 2004;5:429–434.
Gertsch JH, Seto TB, Mor J. Ginkgo biloba for prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent. High Alt Med Biol 2002;3:29–37.
Leadbetter G, Keyes LE, Maakestad KM, Olson S, Tissot van Patot MC, Hackett PH. Ginkgo biloba does—and does not—prevent acute mountain sickness. Wilderness Environ Med 2009;20:66–71.
Ishaque S, Shamseer L, Bukutu C, Vohra S. Rhodiola rosea for physical and mental fatigue: a systematic review. BMC Complement Altern Med 2012;12:70.
Petkov VD, Yonkov D, Mosharoff A. Effects of alcohol aqueous extract from Rhodiola rosea L. roots on learning and memory. Acta Physiol Pharmacol Bulg 1986;12:3–16.
Sun YH, Wang R, Xie H, Yin Q, Jia ZP, Wang C, et al. Effects of Rhodiola Crenulata on physiological and pathological changes in rats after acute exposure to high altitude. Pharm J Chin PLA (Chin) 2014;30:385–388.
Bai MKZ, Guo Y, Bian BDZ, Dong H, Wang T, Luo F, et al. Integripetal rhodiola herb attenuates high altitude-induced pulmonary arterial remodeling and expression of vascular endothelial growth factor in rats. Acta Physiol Sin (Chin) 2011;63:143–148.
Zhang ZH, Feng SH, Hu GD, Cao ZK, Wang LY, Zou XR, et al. Effect of Rhodiola Maxim on preventing moutain reaction—a comparison of cardiopulmonary function in villagers at different altitude areas. China J Chin Mater Med (Chin) 1989;11:47–50.
Wang XW, He JS, Wang DW, Huang ZG, Zhang QG, Luo CR. Treatment of Rhodiola rosea on high altitude polycythemia and the nail fold microcirculation observation: 50 cases of clinical trials. West China J Pharm Sci (Chin) 1994;9:57–59.
Chiu TF, Chen LL, Su DH, Lo HY, Chen CH, Wang SH, et al. Rhodiola crenulata extract for prevention of acute mountain sickness: a randomized, doubleblind, placebo-controlled, crossover trial. BMC Complement Altern Med 2013;13:298.
Yutuo YDGB, ed. Four-volume medical code. Shangha: Shanghai Scientific and Technical Publishers; 1987:206.
Gawa DJ, ed. Commonly used Tibetan medicine prescription. Lhasa: Tibet People's Publishing House; 2009:55.
Cilang SZ. Treating altitude polycythemia, plateau heart disease with plateau hypertension in Tibetan medicine. Clin J Chin Med (Chin) 2011;18:102.
Mi M, Ren QJ, Ba Z, Xi RJC. The clinical efficacy of Tibetan blood-letting therapy in the treatment of 158 cases of HAPC. J Med Pharm Chin Minor (Chin) 2011;9:24–25.
Ciren YZ, Ge Q, De Y, Dawa CR, Yu Z. Efficacy evaluation on Tibetan bloodletting therapy for 48 Zhapeibing (plateau erythrocytosis) cases. Moderniz Tradit Chin Med Mater Med-World Sci Technol (Chin) 2013;5:1002–1004.
Zhou JY, Zhou SW, Du XH, Zeng SY. Protective effect of total flavonoids of Seabuckthorn (Hippophae rhamnoides) in simulated high-altitude polycythemia in rats. Molecules 2012;17:11585–11597.
Wu WB, Meng XL, Zhang Y, Lai XR. Effect of Tibetan compound prescription of Xinsanguo Decoction on plateau erythrocythemia rats. J Guangzhou Univ Tradit Chin Med (Chin) 2010;27:492–494.
Lu MQ, Yu TY, Nima CR, Wu JC, Chen GY, Ciren DJ. Effects of traditional Tibetan medicine Zuomua Decoction and blood-letting therapy on high altitude polycythemia rats. China J Tradit Chin Med Pharm (Chin) 2014;29:2461–2463.
Wu JC, Nima CR, Zhan XH, Duojie RQ, Wei JB, Zhou Q, et al. Morphological study of using traditional Tibetan medicine Zuomua decoction and blood-letting therapy to protect myocard of HAPC rats. J Shandong Univ Tradit Chin Med (Chin) 2013;37:519–521.
Luo DS, ed. New revised Jing Zhu Materia Medica. Chengdu: Sichuan Science and Technology Publishing House; 2004:188–209.
Jin GE, Yun HX, Ma L. Establishment of an animal model of high altitude polycythemia and analyses of its physiological functional responses to hypoxia. J Clin Rehabilitat Tissue Engineer Res (Chin) 2009;13:4713–4716.
Wei W, Wu XM, Li YJ, eds. Experimental methodology of pharmacology. Beijing: People's Medical Publishing House; 2010;70-72.
Monge CC, Whittembury J. Chronic mountain sickness. Johns Hopkins Med J 1976;139:87–89.
Baer RW. The influence of hypoxic hypoxia on coronary blood flow heterogeneity. Adv Exp Med Biol 1994;361:261–270.
Gonzalez G, Celedon G, EscobarM, Sotomayor C, Ferrer V, Benitez D. Red cell membrane lipid changes at 3500 m and on return to sea level. High Alt Med Biol 2005;6:320–326.
Zhang S, Shi J, Sun ZH, Hu CQ. The chemical composition research of Caragana intermedia. J Chin Med Mater (Chin) 2006;29:19–21.
Jin GZ, Piao HS. Studies on chemical constituents from roots of Caragana microphylla. China J Chin Mater Med (Chin) 2007;32:698–700.
Song P, Yang ZL, Bao JY. Studies on the chemical constitutents of Caragana jubata (pall.) Poir. West China J Pharm Sci (Chin) 2009;24:381–382.
Song P, Yang XZ, Yu J. Antifungal activity of pterocarpans from Caragana jubata (pall) poir. Chin J MAP (Chin) 2009;26:691–694.
Xiang T, Uno T, Ogino F, Ai C, Duo J, Sankawa U. Antioxidant constituents of Caragana tibetica. Chem Pharm Bull 2005;53:1204–1206.
Niu Y, Zhang LZ, Niu W, Chen WH, Deng Q, Chai L, et al. Antioxidative activity of extract and flavonoid fractions with different polarity from Caragana microphylla Lam. Flowers. Nat Prod Res Dev 2012;24:1348–1354.
Kang YN, Li YY, Yue YH, Li XR, Shi RB, Ni Y. Extraction technology of total flavonoid from Caragana microphylla and its effect on cerebral ischemia-reperfusion injury in rats. Drug Evaluation Res (Chin) 2013;36:22–25.
Chen X, Da WZM, Ci DDJ, Wang XP, Wang S. The crude drug identification of Tibetan medicine Baxiaga. J Chin Med Mater (Chin) 2011;34:1869–1872.
Liu W, Cheng XM, Wang ZT, Wang CH. Resources, pharmacological activity, toxicity, pharmacokinetics and analysis of vasicine. J Int Pharm Res (Chin) 2013;40:386–395.
Shahwar D, Raza MA, Tariq S, Riasat M, Ajaib M. Enzyme inhibition, antioxidant and antibacterial potential of vasicine isolated from Adhatoda vasica Nees. Pak J Pharm Sci 2012;25:651–656.
Chi F, Deng J, Wang YH. Chemical constituents from Lagotis brevituba. China J Chin Mater Med (Chin) 2010;35:869–871.
Zhang N, Zhou SY, Yin YQ, Yu L, Luo YP, Yang LJ. Antioxidant activities of Lagotis alutacea crude extracts. J Yunnan National Univ (Natural Sci Ed, Chin) 2013;22:5–9.
Li XC, Wang HQ, Liu C, Chen RY. Chemical constituents of Acacia catechu. China J Chin Mater Med (Chin) 2010;35:1425–1427.
Yuan W, Li Y, Liu Y. Pharmacognosic identification of ethno-medicine Acacia catechu (Linn. f.) Willd. Lishizhen Med Mater Med Res (Chin) 2009;20:2802–2803.
Shang WQ, Chen YM, Gao XL, Pu C, Tu PF, Chai XY. Phytochemical and pharmacological advance on Tibetan medicinal plants of Corydalis. China J Chin Mater Med (Chin) 2014;39:1190–1198.
Yang XJ, Qian GS, Mao BL, Huang YP. Study on erythrocyte deformability and spectrin in rats with chronic hypoxia at simulated altitude. J High Altitude Med (Chin) 1997;7:8–10.
Fried W, Goldwasser E, Jacobson LO, Plzak LF. Studies on erythropoiesis. III. Factors controlling erythropoietin production. Proc Soc Exp Biol Med 1957;94:237–241.
Zhang L, Zhang Y, Liu X, Li H, Gu JX, Xiao MC, et al. Expression changes in DNA polymerase γ and mitochondrial DNA damage in aging rat hearts. Chin Heart J (Chin) 2012;24:23–27.
Hearse DJ. Reperfusion of the ischemic myocardium. J Mol Cell Cardiol 1977;8:605–621.
0
Views
373
Downloads
3
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
